Newcells Biotech Ltd

🔬Unlocking Insights into Fibrosis: The FMT Assay This assay provides critical insights into fibrotic diseases, outlining the importance of using culture conditions that promote controlled fibroblast activation and matrix deposition for accurate protein detection and quantification results. 🔍 A comprehensive set of data from a functionally validated high-throughput high-sensitivity FMT assay can: ✔️Accelerate your drug discovery by understanding compound efficacy against fibrosis through the evaluatin of up to 4 parameters across multiple donors ✔️Rapidly screen a library of compounds with high-throughput 384-well un-biased high-content imaging ✔️Capture minute changes in fibrotic marker expression that are critical in gauging anti-fibrotic drug efficacy with laser-based imaging and quantification Learn more here: https://lnkd.in/ePdxzcZm #NewcellsBiotech #Lung #FibrosisResearch #FMT

📣 Registrations are open for our upcoming seminar tour in Cambridge! 🇬🇧 Learn, Discover and Discuss with our technical experts during a morning of scientific innovation, networking and focused 1-2-1 discussion around moving compounds to IND with predictive models💡 Learn more and stay updated on the event page 👇 #Newcells #IND #PredictiveModels

What should you look for when picking your in vitro retina model? 👁 Is important to have microglial cells incorporated into the retinal organoids to give relevant physiological responses. However, this is just the beginning, look for: ✔️Accurately mimicking of the physiology of the human retina for relevant results ✔️Well controlled production process for reliable long term and comparison studies ✔️Readily available model at the development stage that you need to rapidly progress your research Learn more about predictive our retina tissue models here: https://lnkd.in/eNR9vEd3 #Retina #Cells #Modelling #RetinaModelling

📣 Registrations are open for our upcoming seminar tour in Cambridge! 🇬🇧 Learn, Discover and Discuss with our technical experts during a morning of scientific innovation, networking and focused 1-2-1 discussion around moving compounds to IND with predictive models💡 Featuring Dr Colin Brown (Chief Scientific Officer), Dr Valeria Chichagova, PhD (Director of Technology) and Dr Megan Webster, PhD (Head of Lung Platform). 🗓 19 September 📍 Babraham Research Campus Learn more and book your spot 👉 https://lnkd.in/exuiXZKg #Newcells #IND #PredictiveModels

🦠 It is standard practice to test new drug molecules in vivo in two preclinical species to: - gain a more detailed understanding of how they are transported and eliminated through the kidney - mitigate risk of renal toxicity in humans What if you could predict more reliably the response in human and understand cross-species variability ahead of clinical trials? 🤔 The aProximate™ proximal tubule cells model offers a powerful tool to compare transporter activity and drug efficacy and safety across different species to improve in vitro-in vivo extrapolation (IVIVE). Find out more about cross-species comparison of drug handling with near-physiological kidney transporter model: https://lnkd.in/eWaFtAQr #Newcells #InVivo #RenalToxicity #ClinicalTrials

💡 Moving compounds to IND using predictive retina models Get up to speed on the latest insights from a Regulatory, Technology, and Scientific Perspective. We recently brought together a panel of experts to delve into strategies for streamlining the clinical development pipeline, with a special focus on retina-related compounds. 🔬Featuring: Dr Lauren E. Black - Distinguished Scientist/Consultant, working mainly at the first in human (FIH) stage - in high-risk diseases using novel products at Charles River Laboratories Dr Roxana Redis - Associate Science Director, leading the development of the ASO hit to lead platform within Early Discovery at Charles River Laboratories Dr Valeria Chichagova, PhD - Director of Technology, Newcells Biotech Now available on-demand! Watch here ⏯ https://lnkd.in/efYwk2FF #Newcells #VisionResearch #Retina #PredictiveModels

We have just launched our new state-of-the-art imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay. Comprising high-content and high-throughput equipment, the state-of-the-art imaging suite will provide more in-depth and robust in vitro data. The advanced high-throughput high-sensitivity lung FMT assay facilitates customisable and rapid assessment of the efficacy of anti-fibrotic drug candidates. 💬 “The launch of our new imaging suite and enhanced fibrotic disease screening assay is a key step in our strategy to provide innovative, market-leading in vitro models that advance the discovery and safe development of new drugs." - Dr Mike Nicholds, CEO and Co-Founder Find out more 👉 https://lnkd.in/emDSa4qh #Newcells #DrugDevelopment #FMT #InVitroData #HighContentImaging

In case you missed it, we have just launched our new advanced lung FMT assay 🫁 The advanced high-throughput high-sensitivity lung FMT assay facilitates customisable and rapid assessment of the efficacy of anti-fibrotic drug candidates. Building on the success of our existing FMT assay, this advanced version provides data at higher-resolution, with simultaneous assessment of four separate data outputs for more accurate selection and predictivity of drug effects on pulmonary fibrosis. Find out more 👉 https://lnkd.in/ePdxzcZm #Newcells #DrugDevelopment #FMT #LungAssay

Did you miss it? 👀 Find out about the newly launched imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay. Comprising high-content and high-throughput equipment, the state-of-the-art imaging suite provides more in-depth and robust in vitro data. The advanced high-throughput high-sensitivity lung FMT assay facilitates rapid assessment of the efficacy of anti-fibrotic drug candidates enabling easy screening of libraries of compounds. 💬 “The launch of our new imaging suite and accompanying assay is a key step in continuing to provide innovative, market-leading in vitro models that advance the discovery and safe development of new drugs." - Dr Mike Nicholds, CEO and Co-Founder Learn more about our exciting new launch here: https://lnkd.in/gNBAEP3e #Newcells #DrugDevelopment #FMT #InVitroData

Last month Colin Brown (Chief Scientific Officer) and Rhys Powell (Account Manager), travelled to Japan to represent Newcells at the 51st Annual Meeting of the Japanese Society of Toxicology 🇯🇵 Taking place in Fukuoka, the annual meeting brings together experts from around the world dedicated to promoting the understanding, prevention, and mitigation of toxicological hazards to protect human health and the environment. In the below article, Colin shares his key takeaways from the trip, discussing the key themes from the event and the healthy state of the industry in Japan👇 #Newcells #JSOT #Toxicology #KidneyResearch